Disposal concept for LILW in Korea: Characterization methodology and the disposal priority
In: Progress in nuclear energy: the international review journal covering all aspects of nuclear energy, Band 51, Heft 2, S. 327-333
ISSN: 0149-1970
4 Ergebnisse
Sortierung:
In: Progress in nuclear energy: the international review journal covering all aspects of nuclear energy, Band 51, Heft 2, S. 327-333
ISSN: 0149-1970
This study was presented in part as a poster at the meeting of the 3rd WIP Congress in Barcelona, Spain (2004), and the 24th Annual Scientific Meeting of the American Pain Society in the United States (2005). ; BACKGROUND: Botulinum neurotoxin type A (BoNT/A) has been used as an analgesic for myofascial pain syndromes, migraine, and other types of headaches. Although an antinociceptive effect of central or peripheral administration of BoNT/A is suggested, the effect at the spinal level is still unclear. In this study, we evaluated the antinociceptive effect of intrathecally administered BoNT/A on the ICR mice during the formalin test. METHODS: BoNT/A (0.01 U/mouse) was injected intrathecally in ICR mice, and we observed formalin-induced inflammatory pain behaviors at days 1, 4, 7, 10, 14, 21, and 28 after the injection. We also examined the level of calcitonin gene-related peptide (CGRP), phosphorylated extracellullar signal-regulated kinases (p-ERK), and phosphorylated Ca(2+)/calmodulin-dependent protein kinase type 2 (p-CaMK-II) using immunoblot or immunohistochemical analyses before and after BoNT/A intrathecal injection. RESULTS: Even a single intrathecal injection of BoNT/A significantly decreased the nociceptive responses in the first phase (10 and 14 days later) and in the second phase of the formalin test at 1, 4, 7, 10, and 14 days later (P < 0.05) without any locomotor changes. Interestingly, intrathecal BoNT/A attenuated the expression level of CGRP, p-ERK, and p-CaMK-II in the 4th and 5th lumbar spinal dorsal horn at 10 days after injection in comparison with control. CONCLUSIONS: We showed that intrathecally administered BoNT/A may have a central analgesic effect on inflammatory pain through the modulation of central sensitization. BoNT/A, with its long-lasting antinociceptive effect, may be a useful analgesic in inflammatory pain. (Anesth Analg 2011;112:228-35) ; This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2005 to 003-E00204). ; 3
BASE
In: Environmental science and pollution research: ESPR, Band 22, Heft 14, S. 10551-10558
ISSN: 1614-7499
In: Third world quarterly, Band 2, Heft 3, S. 561-614
ISSN: 1360-2241